Management of IgA vasculitis nephritis (Henoch- Schonlein purpura nephritis) in Children

키워드

참고문헌 (82)

1. Pillebout E, "Biomarkers of IgA vasculitis nephritis in children", PLoS One, 12, pp.e0188718~ (2017)
2. Jennette JC, "2012 Revised International Chapel Hill consensus conference nomenclature of Vasculitis", Arthritis Rheum, 65, pp.1~11 (2013)
3. Mills JA, "The American College of Rheumatology 1990 criteria for the classification of vasculitis", Arthritis Rheum, 33, pp.1114~1121 (1990)
4. Ozen S, "EULAR", PRINTO, Ann Rheum Dis, pp.2010, 69[DOI]
5. 정도영, "Clinical Features and Prognosis of Henoch-Schönlein Purpura in Children and Adults: A 13-Year Retrospective Study at a Single Centre", Childhood Kidney Diseases, 21(2), pp.61~68 (2017), 대한소아신장학회
6. Jauhola O, "Renal manifestations of Henoch-Schönlein purpura in a 6-month prospective study of 223 children", Arch Dis Child, 95, pp.877~882 (2010)
7. Saulsbury FT, "Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature", Medicine(Baltimore), 78, pp.395~409 (1999)
8. Calviño MC, "Henoch-Schönlein purpura in children from northwestern Spain : a 20-year epidemiologic and clinical study", Medicine(Baltimore), 80, pp.279~290 (2001)
9. Narchi H, "Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings : a systematic review", Arch Dis Child, 90, pp.16~20 (2005)
10. Wang H, "Urinalysis Monitoring In Children With Henoch-Schönlein Purpura: Is It Time To Revise?", Int J Rheum Dis, 22, pp.1271~1277 (2019)
11. de Almeida JL, "Renal involvement in Henoch-Schönlein purpura : a multivariate analysis of initial prognostic factors", J Pediatr, 83, pp.259~266 (2007)
12. Alfredo CS, "Henoch-Schönlein purpura : recurrence and chronicity", J Pediatr, 83, pp.177~180 (2007)
13. Allen AC, "Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis", Nephrol Dial Transplant, 13, pp.930~934 (1998)
14. Ju T, "A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyl transferase", Proc Natl Acad Sci USA, 99, pp.16613~16618 (2002)
15. He X, "C1GALT1 polymorphisms are associated with Henoch-Schönlein purpura nephritis", Pediatr Nephrol, 27, pp.1505~1509 (2012)
16. Mahajan V, "Serum and urine nitric oxide levels in children with Henoch-Schonlein purpura during activity and remission : a study from North India", Rheumatol Int, 29, pp.1069~1072 (2009)
17. Jiang J, "Inducible nitric oxide synthase gene polymorphisms are associated with a risk of nephritis in Henoch-Schönlein purpura children", Eur J Pediatr, 176, pp.1035~1045 (2017)
18. Ozkaya O., "Renin-angiotensin system gene polymorphisms:association with susceptibility to Henoch-Schonlein purpura and renal involvemene", Clin Rheumatol, 25, pp.861~865 (2006)
19. Amoli MM, "Interleukin 8 gene polymorphism is associated with increased risk of nephritis in cutaneous vasculitis", J Rheumatol, 29, pp.2367~2370 (2002)
20. Nathwani D, "Recurrent post-infective Henoch-Schonlein syndrome: a genetic influence related to HLA B35?", J Infect, 25, pp.205~210 (1992)
21. Amoli MM, "HLA-B35 association with nephritis in Henoch-Schönlein purpura", J Rheumatol, 29, pp.948~949 (2002)
22. Zhou TB, "A meta-analysis of the association between angiotensin-converting enzyme insertion", deletion gene polymorphism and Henoch-Schönlein purpura nephritis risk in Asian children, 2012, pp.30, 315~316
23. He X, "Higher serum angiotensinogen is an indicator of IgA vasculitis with nephritis revealed by comparative proteomes analysis", PLoS One, 10, pp.e0130536~ (2015)
24. Ronkainen J, "Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial", J Pediatr, 149, pp.241~247 (2006)
25. Huber AM, "A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein purpura", BMC Med, 2, pp.7~13 (2004)
26. Dudley J, "Randomized, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP)", Arch Dis Child, 98, pp.756~763 (2013)
27. Hahn D, "Interventions for preventing and treating kidney disease in Henoch-Schonlein Purpura(HSP)", Cochrane Database Syst Rev, 7, pp.Cd005128~ (2015)
28. Coppo R, "Long-term prognosis of Henoch-Scho¨nlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein purpura", Nephrol Dial Transplant, 12, pp.2277~2283 (1997)
29. Goldstein AR, "Long-term followup of childhood Henoch-Schönlein nephritis", Lancet, 339, pp.280~282 (1992)
30. Ronkainen J, "The adult kidney 24 yearsafter childhood Henoch-Schönlein purpura : a retrospective cohort study", Lancet, 360, pp.666~670 (2002)
31. Butani L, "Long-term outcome in children after Henoch-Schonlein purpura nephritis", Clin Pediatr(Phila), 46, pp.505~511 (2007)
32. Fogazzi GB, "Long-term outcome of Schönlein-Henoch nephritis in the adult", Clin Nephrol, 31, pp.60~66 (1989)
33. Huang X, "Significance of histological crescent formation in patients with IgA vasculitis(Henoch-Schönlein purpura)-related nephritis : a cohort in the adult Chinese population", BMC Nephrol, 22, pp.334~343 (2018)
34. Pillebout E, "Henoch-Schönlein Purpura in adults : outcome and prognostic factors", J Am Soc Nephrol, 13, pp.1271~1278 (2002)
35. Niaudet P, "Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis", Pediatr Nephrol, 12, pp.238~243 (1998)
36. Hattori M, "Khono M : Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schonlein purpura nephritis in children", Am J Kidney Dis, 33, pp.427~433 (1993)
37. Shenoy M, "Coulthard MG : Treating severe Henoch-Scho¨nlein and IgA nephritis with plasmapheresis alone", Pediatr Nephrol, 22, pp.1167~1171 (2007)
38. Lan HY, "Atkins RC : Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat", Kidney Int, 47, pp.1303~1309 (1995)
39. Khan SB, "Pusey CD : Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis", Kidney Int, 67, pp.1812~1820 (2005)
40. López-Mejías R, "Genetics of immunoglobulin-A vasculitis(Henoch-Schönlein purpura) : an updated review", Autoimmun Rev, 17, pp.301~315 (2018)
41. Kung JT, "Long noncoding RNAs: Past, present, and future", Genetics, 193, pp.651~669 (2013)
42. Kapusta A, "Volatile evolution of long noncoding RNA repertoires : Mechanisms and biological implications", Trends Genet, 30, pp.439~452 (2014)
43. Pang S, "Differential expression of long non-coding RNA and mRNA in children with Henoch-Schönlein purpura nephritis", Exp Ther Med, 17, pp.621~632 (2019)
44. "Kidney Disease: Improving Global Outcomes. Chapter 11:Henoch-Schonlein purpura nephritis", Kidney Int Suppl(2011), 2, pp.218~220 (2012)
45. Emancipator SN, "Pathology of the kidney", pp.389~476 (1993), Little Brown
46. Davin JC, "What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis?", Kidney Int, 59, pp.823~824 (2001)
47. Andersen RF, "Early high-dose immunosuppression in Henoch-Schönlein nephrotic syndrome may improve outcome", Scand J Urol Nephrol, 43, pp.409~415 (2009)
48. Davin JC, "Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schönlein purpura nephritis", Pediatr Nephrol, 28, pp.1897~1903 (2013)
49. "2018 - KDIGO Clinical Practice Guideline for Glomerulonephritis. KDIGO GN Guideline update - Evidence summary"[URL]
50. Tarshish P, "Henoch-Schönlein purpura nephritis : course of disease and efficacy of cyclophosphamide", Pediatr Nephrol, 19, pp.51~56 (2004)
51. Rauen T, "STOP-IgAN Investigators. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy", N Engl J Med, 373, pp.2225~2236 (2015)
52. Lv J, "Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy : the TESTING randomized clinical trial", JAMA, 318, pp.432~442 (2017)
53. "Management and treatment of glomerular diseases (part 1):conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference", Kid Int, 95, pp.268~280 (2019)
54. Ozen S, "European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative", Rheumatology, 58, pp.1607~1616 (2019)
55. "IgA vasculitis (Henoch-Schönlein purpura): Renal manifestations"[URL]
56. Smith AC, "O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy", J Am Soc Nephrol, 17, pp.3520~3528 (2006)
57. Gharavi AG, "Genomewide association study identifies susceptibility loci for IgA nephropathy", Nat Genet, 43, pp.321~327 (2011)
58. Block GA, "Maintenance of remission following completion of OMS721 treatment in patients with IgA nephropathy (IGAN). Abstract SA-PO278", J Am Soc Nephrol, 28, pp.749~750 (2017)
59. Fellström BC, "Targeted-release budesonide versus placebo in patients with IgA nephropathy(NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial", Lancet, 389, pp.2117~2127 (2017)
60. Suzuki H, "IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis", Kidney Int, 93, pp.700~705 (2018)
61. Maillard N, "Current understanding of the role of complement in IgA nephropathy", J Am Soc Nephrol, 26, pp.1503~1512 (2015)
62. Hisano S, "Iwasaki H : Activation of the lectin complement pathway in Henoch-Schonlein purpura nephritis", Am J Kidney Dis, 45, pp.295~302 (2005)
63. Abou-Ragheb HH, "Plasma levels of the anaphylatoxins C3a and C4a in patients with IgA nephropathy", Henoch-Schonlein nephritis, 1992, pp.62, 22~26
64. "FDA grants orphan drug designation to Omeros' OMS721for treatment of IgA nephropathy" (2017)[URL]
65. Espinosa M, "Association of C4d deposition with clinical outcomes in IgA nephropathy", Clin J Am Soc Nephrol, 9, pp.897~904 (2014)
66. Crayne CB, "Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura : 8 cases and a review of the literature", Pediatr Rheumatol Online J, 16, pp.71~ (2018)
67. Lafayette RA, "A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction", J Am Soc Nephrol, 28, pp.1306~1313 (2017)
68. Tian M, "Heparin calcium treated Henoch-Schonlein purpura nephritis in children through inhibiting hyperfibrinolysis", Ren Fail, 37, pp.1100~1104 (2015)
69. Heeg JE, "Reduction of proteinuria by angiotensin converting enzyme inhibition", Kidney Int, 32, pp.78~83 (1987)
70. Remuzzi A, "Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy", Kidney Int, 39, pp.1267~1273 (1991)
71. Ninchoji T, "Treatment strategies for Henoch-Schönlein purpura nephritis by histological and clinical severity", Pediatr Nephrol, 26, pp.563~569 (2011)
72. Coppo R, "Igace: a placebo‐controlled, randomized trial of angiotensinconverting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria", J Am Soc Nephrol, 18, pp.1880~1888 (2007)
73. Maeba S, "Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules", Ann Allergy Asthma Immunol, 94, pp.670~674 (2005)
74. Wu SH, "Add-on therapy with montelukast in the treatment of Henoch-Schönlein purpura", Pediatr Int, 56, pp.315~322 (2014)
75. Neufeld M, "Galactose deficient IgA1(GD-IgA1)in skin and serum from patients with skin-limited and systemic IgA Vasculitis", J Am Acad Dermatol, 19, pp.30443~30448 (2019)
76. Vuong MT, "Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy", Kidney Int, 78, pp.1281~1287 (2010)
77. Papista C, "Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction", Kidney Int, 88, pp.276~285 (2015)
78. Landecho MF, "Henoch-Schönlein purpura associated with celiac disease", J Am Acad Dermatol, 64, pp.e120~1 (2011)
79. Legendre P, "Anti-endothelial cell antibodies in vasculitis : a systematic review", Autoimmun Rev, 16, pp.146~153 (2017)
80. Fujieda M, "Soluble thrombomodulin and antibodies to bovine glomerular endothelial cells in patients with Henoch-Schonlein purpura", Arch Dis Child, 78, pp.240~244 (1998)
81. Yang YH, "The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-α treatment in children with Henoch-Schönlein purpura", Clin Exp Immunol, 130, pp.352~357 (2002)
82. Inoue CN, "Periodontal and ENT therapy in the treatment of pediatric henoch-schönlein purpura and IgA nephropathy", Adv Otorhinolaryngol, 72, pp.53~56 (2011)

관련 논문AI추천